Evidence map›Paper›PMID 39441907›Full record

ArticleScience translational medicine2024

Characterization of clonal dynamics using duplex sequencing in donor-recipient pairs decades after hematopoietic cell transplantation.

Masumi Ueda Oshima, Jacob Higgins, Isaac Jenkins, Timothy Randolph, Thomas Smith, Charles Valentine, Jesse Salk, Cecilia Yeung, Lan Beppu, Judy Campbell and 5 more

Abstract read
In one paragraph

Article in Science translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Masumi Ueda OshimaClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-2277-1976
Jacob HigginsTwinStrand Biosciences, Seattle, WA 98121, USA.ORCID 0000-0002-4984-5456
Isaac JenkinsClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-3774-3823
Timothy RandolphClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0001-8465-1588
Thomas SmithTwinStrand Biosciences, Seattle, WA 98121, USA.ORCID 0000-0002-8798-7228
Charles ValentineTwinStrand Biosciences, Seattle, WA 98121, USA.ORCID 0000-0001-5630-7368
Jesse SalkDivision of Hematology & Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA.ORCID 0000-0002-7804-0550
Cecilia YeungDepartment of Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA.ORCID 0000-0001-6799-2022
Lan BeppuTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-0401-1159
Judy CampbellClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0009-0003-2953-5324
Paul A CarpenterClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Stephanie J LeeClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-2600-6390
Mary E FlowersClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-1631-0911
Jerald P RadichDivision of Hematology & Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA.
Rainer StorbClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-9343-4099

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STEPHANIE J LEE · 1985 to 2026
$128.4M
Project 3: Stem Cell Allografts for Lymphoid MalignanciesP01CA078902 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SANDMAIER, BRENDA MARIE · 1999 to 2025
$46.1M
Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex SequencingR44CA233381 · NCI · TWINSTRAND BIOSCIENCES, INC. · PI BICKEL, KELLIE · 2018 to 2025
$5.7M
ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" TherapiesUG1CA233338 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2019 to 2025
$4.5M
Understanding and predicting relapse in acute myeloid leukemiaR01CA175008 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RADICH, JERALD PATRICK · 2013 to 2023
$3.9M
NCI NIH HHS P01 CA018029NCI NIH HHS P01 CA078902NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA175008NCI NIH HHS R44 CA233381NCI NIH HHS UG1 CA233338
6 · The paper itself

Abstract

After allogeneic hematopoietic cell transplantation (HCT), a very small number of donor stem cells reconstitute the recipient hematopoietic system, whereas the donor is left with a near-normal pool of stem cells. We hypothesized that the increased replicative stress on transplanted donor cells in the recipient could lead to the disproportionate proliferation of clonal hematopoiesis (CH) variants. We obtained blood samples from 16 related donor-recipient pairs at a median of 33.8 years (range: 6.6 to 45.7) after HCT, including the longest surviving HCT recipients in the world. For 11 of 16 pairs, a donor sample from the time of HCT was available for comparison. We performed ultrasensitive duplex sequencing of genes recurrently mutated in myeloid malignancies and CH, as well as a set of functionally neutral genomic regions representative of human genomic content at large. CH variants were observed in all donors, even those as young as 12 years old. Where donor pre-HCT sample was available, the average mutation rate in donors compared to recipients post-HCT was similar (2.0% versus 2.6% per year, respectively) within genes recurrently mutated in myeloid malignancies. Twenty-two (5.6%) of the 393 variants shared between paired donors and recipients post-HCT showed ≥10-fold higher variant allele frequency (VAF) in the recipient. A longer time since HCT was positively associated with the expansion of shared variant VAFs in the recipient. In conclusion, even decades after HCT, there does not appear to be widespread accelerated clonal expansion in the transplanted cells, highlighting the immense regenerative capacity of the human hematopoietic system.

Indexed as

Hematopoietic Stem Cell TransplantationTissue DonorsAdolescentAdultChildClonal HematopoiesisFemaleHumansMaleMiddle AgedMutationTransplant RecipientsYoung Adult

Identifiers

PMID39441907
PMCPMC11813252

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.